Development and Interim Analysis of a Cystic Fibrosis-Specific Antibiogram

Authors

Claire Elson, Children's Mercy HospitalFollow
Ellen Meier, Children's Mercy HospitalFollow
Douglas Swanson, Children's Mercy HospitalFollow
Rangaraj Selvarangan, Children's Mercy HospitalFollow
Megan Gripka, Children's Mercy HospitalFollow
Christopher M. Oermann, Children's Mercy HospitalFollow

Publication Date

10-2020

Files

Abstract

Antimicrobial therapy is essential to treat cystic fibrosis (CF) lung infections. Empiric antimicrobial selection is generally based on previous culture information and, if available, an institution-specific antibiogram (ABGM). Most institutions antibiograms exclude cultures from individuals with cystic fibrosis, imposing challenges with empiric antimicrobial selection and monitoring susceptibility patterns over time. A cystic fibrosis-specific antibiogram may help drive population-specific antimicrobial selection and improve antimicrobial stewardship.

Disciplines

Infectious Disease | Pathology | Pharmacy and Pharmaceutical Sciences | Pulmonology

Notes

Presented at the 34th Annual North American Cystic Fibrosis Conference, in Philadelphia, PA, October 7-23, 2020.

Recommended Citation

Elson, Claire; Meier, Ellen; Swanson, Douglas; Selvarangan, Rangaraj; Gripka, Megan; and Oermann, Christopher M., "Development and Interim Analysis of a Cystic Fibrosis-Specific Antibiogram" (2020). Posters. 255.
https://scholarlyexchange.childrensmercy.org/posters/255